Alnylam presents new data from HELIOS-B Phase 3 trial
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
Le Lézard17h
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...
Le Lézard16h
Medtronic Evoluttm TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm ...
Sciencing on MSN15h
Here's Why We Still Don't Know How Many Solar Systems Are In The Milky Way
We've known for over 30 years that there are other stellar systems in our galaxy, but we don't have any idea how many there ...